Published: April 24th, 2017
Once again, Cibdol stands out from the sea of CBD oils available on the European market. Following the release of independent CBD oil test results by ICCI (International Cannabis and Cannabinoids Institute) in Prague, Cibdol was one of the few manufacturers to meet the baseline requirements for consumer quality and safety.
This groundbreaking independent study is the first of its kind to evaluate both the quality of CBD on the EU retail market, as well as the composition of various CBD oils. The research was led by professor Jana Hajšlová in cooperation with PFC (Patient Focus Certification) which independently certifies the quality of consumable cannabis products. The research conducted represents an unbiased evaluation of CBD products' potential effects on human subjects.
A predominant focus of this study was to examine the contents of CBD oils for environmental contaminants and polycyclic aromatic hydrocarbons (PAH). PAH’s are classified as carcinogens and can accumulate in CBD oils, thus negating the potential benefits of the CBD supplement.
While PAH testing has been largely conducted on non-human subjects, epidemiological studies have been conclusive on the adverse potential of long-term PAH ingestion. The Agency for Toxic Substances and Disease Registry named PAH's most significant toxic endpoint as cancer, though there are other threats to chronic PAH ingestion. These include conditions affecting the pulmonary, gastrointestinal, renal, and dermatologic systems. Out of the 29 EU CBD oils that were evaluated, only 9 (Cibdol included) passed with “satisfactory” levels of PAH’s that would not contribute to chronic conditions in the future.
This means that only 31% of oils that were tested exceed base level expectations by the Patient Focus Certification. The results were enough to inspire the ICCI to issue an official warning for consumers of CBD and cannabis oils to avoid products with high levels of PAH's and other contaminants. Special attention is being directed toward ill patients using CBD as treatment, unknowingly ingesting carcinogens and contributing to potentially adverse effects.
The second part of the study focused on assessing psychoactive cannabinoid content found in CBD oils in relation to the amounts advertised on product labels. A surprising 34% of CBD oils showed discrepancies between advertised and actual THC content when put under the microscope. Furthermore, 60% of oils did not include any mention of THC at all, despite containing recommended or maximum dosages that could cause a consumer to test positive for THC in the blood.
Even relatively low levels of psychoactive cannabinoids can cause a disruption in an individual’s ability to function normally, especially when they don’t realize they are under the influence. CBD is non-psychoactive, which is why it can be used effectively by so many consumers with different requirements.
These test results have contributed to the ICCI’s fear that ingesting some CBD oils could cause consumers to fail drug tests with noticeable levels of THC in the bloodstream.
Cibdol CBD oils undergo thorough testing to ensure the absence of psychoactive compounds, making our oils safe to consume no matter where or when you use them. For some CBD product manufacturers, independent testing is a new concept, while Cibdol has consistently employed third-party testing to make sure our products are the highest quality and most effective they can be.
Now more than ever, independent testing of CBD products separates Cibdol from the pack of products available on the market. With little oversight up to this point, CBD product manufacturers have been able to cut corners and bypass safety and quality assurance measures in favor of speed and quantity. As the CBD industry continues to expand, it is likely that CBD products, especially consumable ones, will be held to a higher standard.
As Cibdol continues to expand our merchandise to include other iteration of CBD, our oils will continue to undergo the safe intensive purification measures to ensure that only the essential cannabinoids and terpenes are present, without psychoactive compounds or chemical contaminants. The team at Cibdol go to great measures to guarantee of the contents of our products, knowing that a successful finished product is worth the time and effort it takes to get there.
At Cibdol, we have always believed in striving for the best possible product, constantly keeping consumer health and safety in mind. As the ICCI’s results show, Cibdol CBD oil will continue to exceed expectations for CBD consistency and business transparency.